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Background: Several different criteria for the positivity of the flow-assisted Basophil Activation Test (BAT) for the
diagnosis of Neuromuscular Blocking Agents (NMBA) hypersensitivity reactions have been used in past studies. Our
aims were to determine the threshold for BAT positivity expressed as the stimulation index (SI, calculated as the
percentage of activated basophils after stimulation with NMBA divided by the number of basophils with no NMBA
stimulation) and as the percentage of activated basophils, and to determine the sensitivity and specificity of BAT for
NMBAs.
Methods: 22 consenting adult patients with previous intraanaesthetic NMBAs-related hypersensitivity reactions
were tested for the culprit drug. 34 controls who tolerated NMBAs were similarly tested. BAT was performed using
Flow2Cast technique and the up-regulation of the CD63 marker on the basophils was measured using Cell Quest
programme (FACSCalibur Becton Dickinson, USA). Receiver operating characteristics curve (ROC) analysis was
performed.
Results: ROC curve analysis for BAT results versus history yields a stimulation index of 1.76 as the optimal threshold,
with an AUC of 0.81 (CI 95% 0.69-0.93, p < 0.01) and a percentage of activated basophils > 5.01%, with an AUC of
0.84 (CI 95% 0.72-0.95, p < 0.01). Considering both thresholds (the SI≥ 1.76 together with the percentage of
activated basophils > 5%) as diagnostic criteria, 15 patients had positive BAT, the overall BAT sensitivity being
68.18% (CI 95% 45.11-82.26%). None of the controls fulfilled both criteria and the specificity of the test was 100%
(CI 95% 87.35-100%).
Conclusions: With a stimulation index ≥1.76 and a percentage of activated basophils > 5.01% as threshold, the
performance of BAT for NMBAs yields 68.18% sensitivity and 100% specificity.
Keywords: Basophils, Drug hypersensitivity, Flow cytometry, Neuromuscular blocking agentsBackground
Neuromuscular blocking agents (NMBAs) represent
the most common cause of adverse reactions during
anaesthesia, including immediate-type hypersensitivity
reactions [1-3]. The diagnosis of intraanaesthetic ana-
phylaxis implies the retrospective determination of the
responsible agent and of the cross-reactive compounds
[4]. Skin tests coupled with history remain the mainstay of* Correspondence: hagaunatalia@gmail.com
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reproduction in any medium, provided the orthe diagnosis of an IgE-mediated reaction, but though
reliable, they are not infallible [5].
The quantification of basophil activation by flow cytome-
try (the basophil activation test, BAT) has been proven to
be a useful tool for the assessment of the immediate-type
response to allergens mediated by IgE or by other mecha-
nisms in drug allergic patients [6]. There are still open
questions regarding the threshold for positivity [7]. Several
different criteria and cut-offs have been used for BAT with
NMBAs in previous studies, with a percentage of activated
basophils, after stimulation with the allergen, ranging from
4% to 15% or an increase in the percentage of basophils
of more than 10 or 15% above the percentage ofLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the cut-off for BAT positivity expressed as a stimulation
index (the percentage of activated basophils after stimula-
tion with the culprit NMBA divided by the percentage of
activated basophils with no stimulation) has not yet been
established.
The aims of our study were to determine the threshold
for BAT positivity expressed as the stimulation index and
as the percentage of activated basophils and to determine




Ethical approval for this study (Ethical Committee
N° 6/2008) was provided by the Research Ethics Commit-
tee of the University of Medicine and Pharmacy “Iuliu
Hatieganu” Cluj-Napoca (Chairman Prof. Felicia Loghin)
on 2nd Apr 2008. After obtaining patients’ informed
consent, a total of 66 patients with previous general anaes-
thesia (in which NMBAs were administered) and intraa-
naesthetic drug allergy referred to our clinic were
tested in our allergoanaesthesia department.
The inclusion criteria was history suggestive of an
immediate-type hypersensitivity reaction to NMBAs and
positive skin tests. From the 66 patients, 22 consenting
adult patients with previous intraaneaesthetic NMBA-
related allergy suspected by the attending anaesthesi-
ologist and positive skin tests for the culprit drug were
included.
The exclusion criteria were: 23 patients with signs or
symptoms which were not specific for drug hypersensitivity
and had negative skin tests, 9 patients with other drug
allergies (3 midazolam, 4 antibiotics, 2 propofol), one
patient with age less than 18 years, and also, 5 patients
with suspected NMBAs hypersensitivity reactions having
negative skin tests.
The control group included: 34 patients without previous
drug allergies who underwent surgery and tolerated intra-
venous NMBAs in our hospital, who were similarly tested
in vivo and in vitro tests for the NMBAs they received
during surgery.
Skin tests
In vivo tests, the skin prick test (SPT) and the intradermal
test (IDT), were performed using commercially available
solutions of atracurium, pancuronium, rocuronium and
suxamethonium by an allergologist experienced in skin
testing. Normal saline solution (0.9% NaCl) was used to
dilute the commercial substances. The concentrations
used were established as being the maximal non-reactive
concentrations [4,12]. The SPTs and IDTs were performed
in conformity with international recommendations [13].
We used 1% histamine as the positive control and NaCl0.9% as the negative control. The SPT was considered
positive when the wheal diameter was superior to 3 mm
within 20 minutes. For IDT the wheal area was marked
initially and 20 minutes after testing. An increase in
diameter greater than 3 mm or the doubling of the initial
injection wheal represented a positive result [14].
Flow cytometry- the basophil activation test
Flow cytometric analysis of in vitro activated basophils
was performed with Flow2Cast technique, which uses
CCR3 as the basophil identification marker and CD63 as
the marker of basophil activation (Bühlmann Laboratories
AG, Switzerland). The immunologist was blinded regard-
ing the patients’ or controls’ history and skin test results.
Flow cytometry was performed on the same day with skin
testing using all four tested NMBAs for each patient. We
used 6 test tubes containing 50 μl of whole blood. The
blood was collected into K-EDTA venipuncture tubes, up
to the dedicated volume, from antecubital vein (no garrot).
We performed the cell stimulation immediately after collec-
tion of the blood and we did not store the blood samples.
The first sample was mixed with 50 μl of stimulation buffer
as negative control. The next two samples were mixed with
50 μl solution of anti-FcεRI (a highly specific monoclonal
antibody for the IgE receptor) and 50 μl solution of
FMLP (an unspecific cell activator- the chemotactic pep-
tide N-Formyl- Met-Leu), as positive controls. A positive
control higher than 10% basophils indicates that the
patient is not a nonresponder and excludes CCR3 down-
regulation. In the remaining 3 test tubes, 50 μl of NMBAs
solution was added. The tested drug concentrations were
c1, c2 and c3 for atracurium, rocuronium, suxamethonium
and pancuronium (Table 1).
Subsequently, 20 μl staining reagent with two monoclo-
nal antibodies, anti- CCR3-PE (human chemokine receptor
labelled with phycoerythrin) and anti-CD63-FITC (or
Gp53, a glycoprotein expressed on activated basophils),
were added in each tube. The samples were incubated
for 15 min at 37°C in a water bath. A prewarmed lysing
solution of 2 ml was added to each tube and incubated
for 10 minutes at room temperature. After centrifuging
(500 × g, 5 minutes) and washing, the cells were sus-
pended in 300 μl wash buffer. Our laboratory limit of
basophilic cells analyzed for allergies was set to 500.
On our histogram defined by forward scatter and side
scatter, several populations of cells are identified: CCR3-
positive cells (basophils and eosinophils, the main effector
cells in allergic inflammation) and CCR3-negative cells
(lymphocytes, monocytes and granulocytes) [15]. Basophils
are characterised as being the brightest cells (showing
high-density fluorescence with anti-CCR3-PE label) and
having low side-scatter.
The up-regulation of CD63 marker on the baso-
phils was measured using Cell Quest programme







Pancuronium 2 200 c1 500
c2 50
c3 5
Rocuronium 10 50 c1 500
c2 50
c3 5
Suxamethonium 10 100 c1 5
c2 0.5
c3 0.05
Atracurium 1 10 c1 2.5
c2 0.25
c3 0.025
SPT = Skin prick test; IDT = Intradermal test; BAT = Basophil activation test.
Hagau et al. Allergy, Asthma & Clinical Immunology 2013, 9:42 Page 3 of 7
http://www.aacijournal.com/content/9/1/42(FACSCalibur Becton Dickinson San Jose California USA
Analyzer 2001).Statistical analysis
The stimulation index (SI) for all subjects and all concen-
trations was analysed, as well as the percentage of acti-
vated basophils after stimulation with the culprit NMBA.
The stimulation index is calculated as the percentage of
activated basophils after stimulation with NMBA divided
by the percentage of activated basophils with no NMBA
stimulation. Receiver operating characteristics curve (ROC)
analysis was performed with SI and the percentage of acti-
vated basophils as discrimination variables. The reference
standard was considered when the patients had positive
history of allergy to NMBA. The area under curve (AUC)
and p-values were evaluated [16,17]. The cut-off in the
ROC curve is the closest point on the ROC curve to the
point (0,1) which is the point of absolute classification,
where sensitivity and specificity are 1 [18]. For better
prediction, it is obvious to see if using the highest SI
from all three NMBA concentrations for each drug and
for each subject we could obtain an optimal SI as classifica-
tion variable. We performed the ROC curve analysis for the
highest stimulation indexes and for the highest percentage
of activated basophils for all three NMBA concentrations in
patients and controls to calculate the optimal cut-off value.
Sensitivity was calculated as the number of patients with
positive BAT divided by the total number of patients, while
specificity was calculated as the number of controls with
negative BAT divided by the total number of controls.
The result of BAT was considered positive when at
least one of the SI or percentage of activated basophils for
c1, c2 or c3 (the highest stimulation index) was higher
than the threshold.Results
A total of 22 patients with an immediate intraanesthetic
hypersensitivity reaction caused by NMBAs were tested
in vivo and in vitro, as well as 34 surgical patients as
controls, between January 2008-December 2012. Controls
were administered the tested NMBAs intraoperatively
without showing any signs of intraanesthetic drug allergy.
Rocuronium was the culprit agent in 8 patients, atracurium
in 11, suxamethonium in 1 and pancuronium in 2 patients.
Clinical symptoms of NMBA allergy were bronchospasm
in 3, angioedema in 2, urticaria in 4, hypotension in 2 and
anaphylactic shock in 11 patients (Table 2). All patients
presented positive skin tests. None of the healthy controls
presented a positive skin test (Table 3). None of the
subjects presented systemic reactions during the skin tests.
ROC curve analysis for BAT performed with the highest
stimulation index from the three NMBAs concentrations
used together versus history yields a stimulation index of
1.76 as the optimal threshold for BAT positivity, with an
AUC of 0.81 (CI 95% 0.69-0.93, p < 0.01) (Figure 1). With
a cut-off of 1.76 as diagnostic criteria, there were 17 posi-
tive BAT in patients and 6 positive BAT for controls, thus
the sensitivity of BAT was 77.27% (CI 95% 54.17-91.31%)
and the specificity 82.35% (CI 95% 64.83-92.61%) when
using the optimal SI generated by the ROC curve as diag-
nostic criteria alone. For rocuronium, from the 8 patients
6 were BAT positive, with 75% sensitivity. From the 11 pa-
tients with atracurium-induced anaphylaxis 9 had positive
BAT, with 81.81% sensitivity.
In order to find the optimal threshold expressed as the
percentage of activated basophils, we performed the ROC
curve using the highest Ba% value for BAT from the three
drug concentrations for each patient (Figure 1). The opti-
mal threshold value for BAT positivity is a percentage of
activated basophils > 5.01%, with an AUC of 0.84 (CI 95%
0.72-0.95, p < 0.01), as revealed by performing the ROC
curve. Considering Ba% > 5.01% as the threshold for BAT
positivity, there were 17 BAT positivities among the 22
patients and 5 out of the 34 controls had positive BAT, with
an overall 77.27% (CI 95% 54.17-91.31%) BAT sensitivity
and 85.29% (CI 95% 68.16-94.45%) specificity. Three pa-
tients were BAT positive only considering a percentage
of activated basophils > 5.01%. From the 8 allergic reactions
caused by rocuronium, 7 were confirmed by a positive
BAT (87.50% sensitivity), for atracurium BAT confirmed 7
out of the 11 allergic reactions (63.63% sensitivity). Figure 2
provides the flow cytometry dot polt for one of the patients
with rocuronium-induced anaphylactic shock, showing
positive results for all three rocuronium concentrations.
The use of a SI ≥ 1.76 or a Ba% > 5.01% in the interpret-
ation of BAT results shows no differences between the
AUC (p = 0.69).
Considering both thresholds obtained from the ROC
curves (the SI ≥ 1.76 together with the percentage of
Table 2 Positive history patients’ data
Number Sex Substance Clinical symptoms SPT IDT SI Ba%
1 M Rocuronium Shock Positive 6.06 10.73
2 M Suxamethonium Shock Positive 2.10 31.56
3 M Pancuronium Shock Negative Positive 1.06 7.15
4 M Rocuronium Urticaria Positive 2.60 13.00
5 F Pancuronium Bronchospasm Negative Positive 3.23 17.11
6 F Rocuronium Shock Positive 2.05 14.48
7 F Atracurium Shock Positive 0.93 2.17
8 F Rocuronium Shock Negative Positive 5.22 25.15
9 F Atracurium Shock Positive 7.68 20.50
10 F Atracurium Angioedema Negative Positive 1.86 3.54
11 F Atracurium Angioedema Positive 1.99 13.29
12 F Atracurium Shock Positive 4.81 7.93
13 F Atracurium Urticaria Positive 3.89 8.91
14 F Atracurium Hypotension Negative Positive 2.01 6.48
15 F Rocuronium Hypotension Positive 0.52 2.14
16 M Rocuronium Urticaria Positive 4.62 18.68
17 M Atracurium Bronchospasm Negative Positive 9.11 20.67
18 F Rocuronium Bronchospasm Positive 1.60 7.19
19 F Atracurium Shock Negative Positive 5.03 5.08
20 F Atracurium Shock Negative Positive 2.62 3.54
21 F Rocuronium Urticaria Negative Positive 4.82 10.26
22 F Atracurium Shock Negative Positive 1.48 2.67
M=Masculine; F = Feminine; Ba% = The highest percentage of activated basophils from c1, c2 and c3 concentrations for each NMBA; SPT = Skin prick test;
IDT = Intradermal test; SI = The highest stimulation index from c1, c2 and c3 concentrations for each NMBA.
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had positive BAT. Thus, the overall BAT sensitivity
performed with the three NMBAs concentrations was
68.18% (CI 95% 45.11-85.26%). None of the controls ful-
filled both criteria and the specificity of the test was
100% (CI 95% 87.35-100%).Discussion
NMBAs-induced anaphylaxis is a rare intraanesthetic
event having an estimated incidence of 250.9/ 1 million
anaesthetics, with life-threatening clinical symptoms like
hypotension, shock or cardiac arrest in 36.39% cases of
non-IgE-mediated reactions and 84.04% IgE-mediated
allergic reactions [3].
The diagnostic management of anaphylaxis from NMBAs
rests upon an evocative history corroborated by appropiate
skin tests, which are reliable but have no absolute diagnos-
tic accuracy [4]. For example, when the skin test is nega-
tive, it is virtually impossible to determine whether it is a
false-negative test unless the agent is administered [19].
However, the performance of challenge tests for NMBAs
is restricted because of ethical and practical limitations[20]. For NMBAs, allergological skin tests still remain the
current reference test [8].
Basophil activation based upon the expression of CD63
in the presence of specific allergens was found to be of im-
portance for the diagnosis of IgE-mediated hypersensitivity
[1]. We chose to perform BAT using CD63 as activation
marker as this seems to be the most sensitive for NMBAs
[11,21]. In previous studies the sensitivity of BAT for
NMBAs was 36-92%, while the specificity was 93-100%,
depending on the chosen threshold for positivity [1,8-11].
There are still many open questions regarding the most
appropiate threshold for positivity. In the past, thresholds
for positivity often were set arbitrarily [7]. For other drugs,
the threshold expressed as a stimulation index ≥2 has
been established by ROC curve analysis. A SI ≥ 2 together
with a percentage of activated basophils of more than 5%
(in order to avoid small, un-specific stimulation) represent
current criteria for BAT positivity for antibiotics and non-
steroidal anti-inflammatory drugs [22-24]. These criteria
are also recommended by the manufacturers for NMBAs,
though for NMBAs the threshold expressed as a stimula-
tion index has not been established by the performance of
ROC curves including a large number of patients.
Table 3 Controls’ data
Number Sex Substance SI Ba%
1 M Suxamethonium 1.15 5.01
2 M Atracurium 1.57 4.00
3 M Pancuronium 1.71 2.09
4 M Pancuronium 1.90 3.90
5 M Suxamethonium 1.04 2.72
6 M Atracurium 1.51 3.09
7 M Rocuronium 1.87 4.54
8 M Atracurium 1.33 3.22
9 M Pancuronium 1.36 3.76
10 M Rocuronium 1.49 3.02
11 M Atracurium 0.83 1.30
12 M Pancuronium 1.76 3.60
13 M Pancuronium 1.67 3.40
14 F Pancuronium 1.03 3.32
15 F Atracurium 1.63 3.93
16 F Rocuronium 1.69 3.49
17 F Rocuronium 1.33 6.70
18 F Suxamethonium 1.19 6.00
19 F Pancuronium 1.13 4.00
20 F Rocuronium 1.38 5.59
21 F Suxamethonium 1.02 1.80
22 F Pancuronium 1.05 4.00
23 F Rocuronium 0.85 3.25
24 F Suxamethonium 1.37 4.05
25 F Atracurium 2.92 3.68
26 F Rocuronium 1.21 2.96
27 F Suxamethonium 1.32 3.23
28 F Atracurium 1.29 3.16
29 F Suxamethonium 1.99 3.14
30 F Atracurium 2.24 3.59
31 F Rocuronium 1.23 5.75
32 F Pancuronium 1.55 0.59
33 F Rocuronium 1.76 0.67
34 F Atracurium 2.29 0.87
M=Masculine; F = Feminine; Ba% = The highest percentage of activated
basophils from c1, c2 and c3 concentrations for each NMBA; SI = The highest





















Figure 1 ROC curve for BAT stimulation index (SI) and
percentage of activated basophils (Ba%) versus history for
patients and controls. Ba% = the highest percentage of activated
basophils from c1, c2 and c3 concentrations for each NMBA; SI = the
highest stimulation index from c1, c2 and c3 concentrations for
each NMBA; Se = sensitivity; Sp = specificity.
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instead predefined and arbitrarily chosen cut-offs, and these
are adequately defined by performing receiver operating
characteristics (ROC) curves [25]. The ideal way to choose
a cut-off for a given test is by ROC curve analysis [26].
This enables the precise calculation of the most discrim-
inative cut-off value [27]. The cut-off for BAT positivity
expressed as stimulation indexes and established by theuse of ROC curve analysis has not been assessed in most
published studies on NMBAs [1,9-11]. The only published
ROC curve for NMBAs included 14 patients with
rocuronium-induced anaphylaxis and 8 healthy controls
and a sensitive cut-off of 4% activated basophils has been
suggested for rocuronium [8].
The inclusion of sufficient numbers of well characterised
allergic patients and healthy, exposed control individuals is
critical to perform ROC curve analysis [20]. In our study,
22 patients with intraanesthetic immediate-type allergic
reactions after the administration of NMBAs and positive
skin tests for the culprit drug on subsequent testing, as
well as 34 healthy controls, were included. All controls
presented negative skin test for NMBAs and tolerated
them without signs of hypersensitivity. The optimal thresh-
old generated by the ROC curve analysis was 1.76 when
the stimulation index was analysed and 5.01% when the
percentage of activated basophils was considered.
Anaphylaxis from NMBAs can be life-threatening and
it is critical to establish a sensitive cut-off as false negative
results can have dramatic consequences [8,20].
Using both criteria for diagnosis, similarly to antibiotic
and anti-inflammatory drugs and according to the manu-
facturers’ recommendations, BAT has 68.18% sensitivity
and 100% specificity for NMBAs. The lower observed BAT
sensitivity might be due to several reasons. First, NMBAs
sensitivity might be lost in time [1]. Second, basophil
activation is not directly comparable to mast cell reactivity,
the letter being the major effector cells in some of the
hypersensitive patients [11]. Moreover, false negative results
might be explained by a recent exposure to cross-reactive
compounds with similar epitopes and the subsequent








Figure 2 Flow cytometry dot plot result in a patient with rocuronium-induced anaphylactic shock. Pb = initial plot identifying basophils;
Pcn = negative control; Pcp1 = positive control with FcεRI; Pcp2 = positive control with N-formyl-Met-Leu; Pc1 = allergen rocuronium 500 μg/mL;
Pc2 = allergen rocuronium 50 μg/mL; Pc3 = allergen rocuronium 5 μg/mL.
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different sensitivities for each NMBA, but the limited
number of cases for each drug does not allow us to draw a
definitive conclusion. A higher number of cases are needed
in order to increase the power of the study, a target difficult
to obtain as anaphylaxis from NMBAs is a low-prevalence
disease. The inclusion of a higher number of patients
by performing multicenter studies might overcome this
limitation of our study.
Conclusion
With a stimulation index ≥1.76 and a percentage of
activated basophils > 5.01% as threshold, the performance
of BAT for NMBAs yields 68.18% sensitivity and 100%
specificity.
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